Shattuck Labs names Shoba Ravichandran senior vice president, clinical development

Bitget2026/10/01 11:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Shattuck Labs named Shoba Ravichandran as senior vice president, clinical development to lead the SL-325 hidradenitis suppurativa program.
Ravichandran previously spent more than a decade at Novartis, most recently as senior global program clinical head.
She led the global approval of Cosentyx in hidradenitis suppurativa, also led Phase 3 start-up for remibrutinib in the disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010700PRIMZONEFULLFEED9837550) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Shattuck Labs names Shoba Ravichandran senior vice president, clinical development

You may also like

Crypto prices